Individualization of controlled ovarian stimulation in IVF from theory to practice

Citation Report

#	Article	IF	Citations
1	Improved cycle outcomes after laparoscopic ovarian diathermy in hyper-responder patients with previous ART failure. Gynecological Endocrinology, 2014, 30, 881-884.	1.7	7
2	Reply: The two sides of the individualization of controlled ovarian stimulation. Human Reproduction Update, 2014, 20, 614-615.	10.8	2
3	The two sides of the individualization of controlled ovarian stimulation. Human Reproduction Update, 2014, 20, 614-614.	10.8	4
4	The Bologna criteria for the definition of poor ovarian responders: is there a need for revision?. Human Reproduction, 2014, 29, 1842-1845.	0.9	123
5	Reply: GnRH agonist triggering in high-risk patients. Human Reproduction, 2014, 29, 1598-1599.	0.9	1
6	Best Protocol for Controlled Ovarian Hyperstimulation in Assisted Reproductive Technologies: Fact or Opinion?. Seminars in Reproductive Medicine, 2014, 32, 262-271.	1.1	21
7	Current Resources for Evidence€Based Practice, November/December 2014. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2014, 43, 762-770.	0.5	0
8	New reagents for detecting low antimüllerian hormone serum levels in perimenopausal women. Menopause, 2014, 21, 1261-1262.	2.0	0
9	Maximizing the clinical utility of antimüllerian hormone testing in women's health. Current Opinion in Obstetrics and Gynecology, 2014, 26, 226-236.	2.0	30
10	Recent progress in the utility of anti-Müllerian hormone in female infertility. Current Opinion in Obstetrics and Gynecology, 2014, 26, 162-167.	2.0	11
11	The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin. Gynecological Endocrinology, 2014, 30, 444-450.	1.7	20
12	Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction. Reproductive BioMedicine Online, 2014, 28, 183-190.	2.4	9
13	Counting ovarian follicles: updated threshold for diagnosis of hyperandrogenic anovulation. Ultrasound in Obstetrics and Gynecology, 2014, 44, 131-134.	1.7	22
14	Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Human Reproduction Update, 2014, 20, 688-701.	10.8	491
15	Anti-mullerian hormone in the management of infertility. Middle East Fertility Society Journal, 2014, 19, 1-7.	1.5	0
17	Follicular and endocrine dose responses according to anti€Müllerian hormone levels in <scp>IVF</scp> patients treated with a novel human recombinant <scp>FSH</scp> (<scp>FE</scp>) Tj ETQq1 1 0.784314 rgBT /Ove		
18	A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist survey. Reproductive Biology and Endocrinology, 2015, 13, 133.	3.3	25
19	Serum anti€Müllerian hormone in subfertile women. Acta Obstetricia Et Gynecologica Scandinavica, 2015, 94, 1307-1312.	2.8	21

#	Article	IF	Citations
20	Ovarian response biomarkers. Current Opinion in Obstetrics and Gynecology, 2015, 27, 182-186.	2.0	38
21	Predictive Value of AMH, FSH and AFC for Determining Ovarian Response in Vietnamese Women Undergoing Assisted Reproductive Technologies: A Prospective Study. Journal of Fertilization in Vitro IVF Worldwide Reproductive Medicine Genetics & Stem Cell Biology, 2015, 03, .	0.2	0
22	Utilidad de la determinación de la reserva ovárica como predictor de la posibilidad de embarazo espontáneo: Revisión sistemática. Revista Chilena De Obstetricia Y Ginecologia, 2015, 80, 421-425.	0.1	0
23	Reclaiming fertility awareness methods to inform timed intercourse for HIV serodiscordant couples attempting to conceive. Journal of the International AIDS Society, 2015, 18, 19447.	3.0	13
24	Cell-free DNA in Human Follicular Microenvironment: New Prognostic Biomarker to Predict in vitro Fertilization Outcomes. PLoS ONE, 2015, 10, e0136172.	2.5	25
25	Prevention of Ovarian Hyperstimulation Syndrome: A Review. Obstetrics and Gynecology International, 2015, 2015, 1-10.	1.3	58
26	Prognostic Factors for IVF Success: Diagnostic Testing and Evidence-Based Interventions. Seminars in Reproductive Medicine, 2015, 33, 065-076.	1.1	13
27	Antral follicle count as a predictor of ovarian responsiveness in women with endometriomas or with a history of surgery for endometriomas. Fertility and Sterility, 2015, 103, 1544-1550.e3.	1.0	16
28	Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study. Journal of Assisted Reproduction and Genetics, 2015, 32, 931-937.	2.5	77
29	Best Practices for Controlled Ovarian Stimulation in In Vitro Fertilization. Seminars in Reproductive Medicine, 2015, 33, 077-082.	1.1	36
30	The necessity to define the sub-optimal responders. Human Reproduction, 2015, 30, dev254.	0.9	3
31	Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. Human Reproduction Update, 2015, 21, 698-710.	10.8	188
32	A multi-centre phase 3 study comparing efficacy and safety of Bemfola® versus Gonal-f® in women undergoing ovarian stimulation for IVF. Reproductive BioMedicine Online, 2015, 30, 504-513.	2.4	70
33	Endometrial pattern, but not endometrial thickness, affects implantation rates in euploid embryo transfers. Fertility and Sterility, 2015, 104, 620-628.e5.	1.0	91
34	Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays. Fertility and Sterility, 2015, 104, 1016-1021.e6.	1.0	96
35	Performance of the two new fully automated anti-Müllerian hormone immunoassays compared with the clinical standard assay. Human Reproduction, 2015, 30, 1918-1926.	0.9	78
36	Clinical Assessment of Ovarian Toxicity. , 2015, , 35-45.		0
37	The Ideal Stimulation Protocol: Is There One?. Journal of Obstetrics and Gynecology of India, 2015, 65, 357-361.	0.9	5

#	Article	IF	Citations
38	Ovarian response is affected by a specific histidine-rich glycoprotein polymorphism: a preliminary study. Reproductive BioMedicine Online, 2015, 30, 74-81.	2.4	10
39	Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study. Reproductive BioMedicine Online, 2015, 31, 347-355.	2.4	13
40	Fertility preservation in women with endometriosis: for all, for some, for none?. Human Reproduction, 2015, 30, 1280-1286.	0.9	96
41	Menstrual cycle length: a surrogate measure of reproductive health capable of improving the accuracy of biochemical/sonographical ovarian reserve test in estimating the reproductive chances of women referred to ART. Reproductive Biology and Endocrinology, 2015, 13, 28.	3.3	27
42	Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. Fertility and Sterility, 2015, 103, 923-930.e1.	1.0	110
43	Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool. Fertility and Sterility, 2015, 103, 1074-1080.e4.	1.0	77
44	Controlled Ovarian Stimulation for Follicular Recruitment and Oocyte Recovery in IVF. , 2015, , 21-31.		0
46	Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies. Journal of Assisted Reproduction and Genetics, 2015, 32, 1801-1810.	2.5	38
47	The sub-optimal response to controlled ovarian stimulation: manageable or inevitable?. Human Reproduction, 2015, 30, 2009-2010.	0.9	6
48	Niveles séricos de hormona antimulleriana como predictor de baja respuesta en mujeres sometidas a ciclos de fecundación in vitro. Medicina Reproductiva Y Embriología Clínica, 2015, 2, 9-16.	0.1	1
49	The ICSI procedure from past to future: a systematic review of the more controversial aspects. Human Reproduction Update, 2016, 22, dmv050.	10.8	121
50	Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone. Human Reproduction, 2015, 30, 170-178.	0.9	52
51	Hormonal and Clinical Predictors for Post–egg Retrieval Pain in Women Undergoing Assisted Reproductive Technology Procedures. Clinical Journal of Pain, 2016, 32, 313-320.	1.9	1
52	Clinical Applications of Gonadotropins in the Female: Assisted Reproduction and Beyond. Progress in Molecular Biology and Translational Science, 2016, 143, 85-119.	1.7	34
53	No common denominator: a review of outcome measures in IVF RCTs. Human Reproduction, 2016, 31, 2714-2722.	0.9	45
54	Individualization of controlled ovarian stimulation in vitro fertilization using markers of ovarian reserve: a systematic review. Reproducao E Climaterio, 2016, 31, 128-133.	0.1	0
55	Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertility and Sterility, 2016, 105, 1488-1495.e1.	1.0	187
56	The risk of embryo-endometrium asynchrony increases with maternal age after ovarian stimulation and IVF. Reproductive BioMedicine Online, 2016, 33, 50-55.	2.4	42

#	ARTICLE	IF	CITATIONS
57	Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation. Fertility and Sterility, 2016, 105, 690-696.	1.0	10
58	Both slowly developing embryos andÂa variable pace of luteal endometrial progression may conspire to prevent normal birth inÂspite of a capable embryo. Fertility and Sterility, 2016, 105, 861-866.	1.0	45
59	Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-MÃ¼llerian hormone. Gynecological Endocrinology, 2016, 32, 625-628.	1.7	4
60	Anti-MÃ¼llerian hormone and polycystic ovary syndrome. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 38-45.	2.8	49
61	Outcomes of anti-MÃ¼llerian hormone-tailored ovarian stimulation protocols in inÂvitro fertilization/intracytoplasmic sperm injection cycles in women of advanced age. Taiwanese Journal of Obstetrics and Gynecology, 2016, 55, 239-243.	1.3	4
62	Live birth and perinatal outcomes following stimulated and unstimulated IVF: analysis of over two decades of a nationwide data. Human Reproduction, 2016, 31, 2261-2267.	0.9	54
64	Comparative evaluation of three new commercial immunoassays for anti-MÃ¼llerian hormone measurement. Human Reproduction, 2016, 31, 2796-2802.	0.9	73
65	Individualized follicleâ€stimulating hormone dosing and inÂvitro fertilization outcome in agonist downregulated cycles: a systematic review. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 1333-1344.	2.8	15
66	An update on the prevention of ovarian hyperstimulation syndrome. Women's Health, 2016, 12, 496-503.	1.5	13
67	Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 207, 94-99.	1.1	36
68	Three Wishes for the Future of Point-of-Care Testing. Point of Care, 2016, 15, 172-175.	0.4	0
69	Anti-MÃ¼llerian hormone concentrations and antral follicle counts for the prediction of pregnancy outcomes after intrauterine insemination. International Journal of Gynecology and Obstetrics, 2016, 133, 64-68.	2.3	14
70	MicroRNA Expression is Altered in Granulosa Cells of Ovarian Hyperresponders. Reproductive Sciences, 2016, 23, 1001-1010.	2.5	17
71	Serum Stem Cell Factor Assay in Elderly Poor Responder Patients Undergoing IVF: A New Biomarker to Customize Follicle Aspiration Cycle by Cycle. Reproductive Sciences, 2016, 23, 61-68.	2.5	19
72	Infertile women below the age of 40 have similar anti-MÃ¼llerian hormone levels and antral follicle count compared with women of the same age with no history of infertility. Human Reproduction, 2016, 31, 1034-1045.	0.9	52
73	Usefulness of oocyte accumulation in low ovarian response for PGS. Gynecological Endocrinology, 2016, 32, 577-580.	1.7	7
74	Trends in â€˜poor responderâ€™ research: lessons learned from RCTs in assisted conception. Human Reproduction Update, 2016, 22, 306-319.	10.8	65
75	IVF results in patients with very low serum AMH are significantly affected by chronological age. Journal of Assisted Reproduction and Genetics, 2016, 33, 603-609.	2.5	40

#	Article	IF	Citations
76	Anti‐Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?. Reproductive Medicine and Biology, 2016, 15, 127-136.	2.4	52
77	The use of ovarian reserve markers in IVF clinical practice: a national consensus. Gynecological Endocrinology, 2016, 32, 1-5.	1.7	57
78	Female Infertility. , 2016, , 2260-2274.e4.		1
80	The cutoff values of serum AMH levels and starting recFSH doses for the individualization of IVF treatment strategies. Gynecological Endocrinology, 2017, 33, 467-471.	1.7	2
81	Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. Expert Review of Quality of Life in Cancer Care, 2017, 2, 47-59.	0.6	13
82	A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive BioMedicine Online, 2017, 34, 429-438.	2.4	68
84	Genetics of gonadotropins and their receptors as markers of ovarian reserve and response in controlled ovarian stimulation. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 44, 15-25.	2.8	29
85	Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Human Reproduction, 2017, 32, 544-555.	0.9	53
87	New AMH assay allows rapid point of care measurements of ovarian reserve. Gynecological Endocrinology, 2017, 33, 638-643.	1.7	11
88	Management of ovarian stimulation for IVF: narrative review of evidence provided for World Health Organization guidance. Reproductive BioMedicine Online, 2017, 35, 3-16.	2.4	27
89	Non-equivalence of anti-Müllerian hormone automated assays—clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. Human Reproduction, 2017, 32, 1710-1715.	0.9	37
90	The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction, 2017, 32, 811-819.	0.9	34
92	Premature Ovarian Insufficiency. , 2017, , 197-215.		0
93	Retrospective cohort study: AMH is the best ovarian reserve markers in predicting ovarian response but has unfavorable value in predicting clinical pregnancy in GnRH antagonist protocol. Archives of Gynecology and Obstetrics, 2017, 295, 763-770.	1.7	29
94	Individual luteolysis post GnRH-agonist-trigger in GnRH-antagonist protocols. Gynecological Endocrinology, 2017, 33, 261-264.	1.7	10
95	Patient-tailored ovarian stimulation for in vitro fertilization. Fertility and Sterility, 2017, 108, 585-591.	1.0	23
96	Ovarian response prediction in controlled ovarian stimulation for IVF using anti-Müllerian hormone in Chinese women. Medicine (United States), 2017, 96, e6495.	1.0	20
97	Anti-Müllerian hormone levels and fecundability in women with a natural conception. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 217, 44-52.	1.1	13

#	ARTICLE	IF	CITATIONS
98	GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome. Journal of Obstetrics and Gynecology of India, 2017, 67, 270-274.	0.9	3
99	The carriers of the A/G-G/G allelic combination of the c.2039 A>G and c.-29 G>A FSH receptor polymorphisms retrieve the highest number of oocytes in IVF/ICSI cycles. Journal of Assisted Reproduction and Genetics, 2017, 34, 263-273.	2.5	9
100	Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis. Human Reproduction, 2017, 32, 2485-2495.	0.9	70
101	Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder. Human Reproduction, 2017, 32, 2506-2514.	0.9	80
102	How much variation in oocyte yield after controlled ovarian stimulation can be explained? A multilevel modelling study. Human Reproduction Open, 2017, 2017, hox018.	5.4	17
103	Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health. Human Reproduction, 2017, 32, 1549-1555.	0.9	9
104	The Impact on Ovarian Reserve of CO_2 Laser Fiber Vaporization in the Treatment of Ovarian Endometrioma: A Prospective Clinical Trial. Journal of Endometriosis and Pelvic Pain Disorders, 2017, 9, 206-210.	0.5	10
105	Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSHâ€‰+â€‰Luteinizing Hormone, Human Menopausal Gonadotropin or FSHâ€‰+â€‰Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the â€œPersonalizedâ€•Medicine Era: A Meta-analysis. Frontiers in Endocrinology, 2017, 8, 114.	3.5	76
106	Successful Pregnancies After Adequate Hormonal Replacement in Patients With Combined Pituitary Hormone Deficiencies. Journal of the Endocrine Society, 2017, 1, 1322-1330.	0.2	14
107	How to personalize ovarian stimulation in clinical practice. Journal of the Turkish German Gynecology Association, 2017, 18, 148-153.	0.6	10
108	Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI. In Vivo, 2017, 31, 231-238.	1.3	23
109	The use of antiâ€Mâ€¼llerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and â€counseling. Acta Obstetricia Et Gynecologica Scandinavica, 2018, 97, 1105-1113.	2.8	19
110	Clinical application of serum antiâ€Mâ€¼llerian hormone as an ovarian reserve marker: A review of recent studies. Journal of Obstetrics and Gynaecology Research, 2018, 44, 998-1006.	1.3	39
111	Discordance between serum anti-Mâ€¼llerian hormone concentrations and antral follicle counts: not only technical issues. Human Reproduction, 2018, 33, 1141-1148.	0.9	31
112	Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). The Cochrane Library, 2018, 2018, CD012693.	2.8	93
113	Pharmacogenetics of G-protein-coupled receptors variants: FSH receptor and infertilityÂtreatment. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 189-200.	4.7	22
114	Differential response of AMH to GnRH agonist among individuals: the effect on ovarian stimulation outcomes. Journal of Assisted Reproduction and Genetics, 2018, 35, 467-473.	2.5	9
115	Individualized controlled ovarian stimulation in expected poor-responders: an update. Reproductive Biology and Endocrinology, 2018, 16, 20.	3.3	66

#	Article	IF	Citations
116	The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropinâ€releasing hormone antagonist ovarian stimulation protocol. International Journal of Gynecology and Obstetrics, 2018, 142, 97-103.	2.3	11
117	Objective multicentre performance of the automated assays for AMH and estimation of established critical concentrations. Human Fertility, 2018, 21, 269-274.	1.7	11
118	Successful controlled ovarian stimulation and vitrification of oocytes in an adolescent diagnosed with myelodysplastic/pre-malignant clone with monosomy 7. Human Fertility, 2018, 21, 39-44.	1.7	5
119	Ovarian volume and PCOS: a controversial issue. Gynecological Endocrinology, 2018, 34, 229-232.	1.7	17
120	Characterization of a suboptimal IVF population and clinical outcome after two IVF cycles. Gynecological Endocrinology, 2018, 34, 125-128.	1.7	4
121	Counting ovarian antral follicles by ultrasound: a practical guide. Ultrasound in Obstetrics and Gynecology, 2018, 51, 10-20.	1.7	90
122	Establishment and validation of a score to predict ovarian response to stimulation in IVF. Reproductive BioMedicine Online, 2018, 36, 26-31.	2.4	23
123	Luteal phase serum progesterone levels after GnRH-agonist trigger - how low is still high enough for an ongoing pregnancy?. Gynecological Endocrinology, 2018, 34, 195-198.	1.7	7
124	The utility of anti-MÃ¼llerian hormone in women with chronic kidney disease, on haemodialysis and after kidney transplantation. Reproductive BioMedicine Online, 2018, 36, 219-226.	2.4	23
125	Age-related decline in AMH is assay dependent limiting clinical interpretation of repeat AMH measures across the reproductive lifespan. Gynecological Endocrinology, 2018, 34, 115-119.	1.7	6
127	GnRH agonist long protocol versus GnRH antagonist protocol for various aged patients with diminished ovarian reserve: A retrospective study. PLoS ONE, 2018, 13, e0207081.	2.5	30
129	Ovarian Stimulation in<i>in vitro</i>Fertilization. Journal of Mammalian Ova Research, 2018, 35, 35-41.	0.1	0
130	Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on womanâ€™s age and markers of ovarian reserve. Archives of Gynecology and Obstetrics, 2018, 298, 1029-1035.	1.7	67
131	Two Hormones for One Receptor: Evolution, Biochemistry, Actions, and Pathophysiology of LH and hCG. Endocrine Reviews, 2018, 39, 549-592.	20.1	118
132	Understanding Ovarian Hypo-Response to Exogenous Gonadotropin in Ovarian Stimulation and Its New Proposed Markerâ€"The Follicle-To-Oocyte (FOI) Index. Frontiers in Endocrinology, 2018, 9, 589.	3.5	106
133	Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 231, 192-197.	1.1	4
134	Mild ovarian stimulation with letrozole plus fixed dose human menopausal gonadotropin prior to IVF/ICSI for infertile non-obese women with polycystic ovarian syndrome being pre-treated with metformin: a pilot study. Reproductive Biology and Endocrinology, 2018, 16, 89.	3.3	10
135	Cumulative live birth rate in freeze-all cycles is comparable to that of a conventional embryo transfer policy at the cleavage stage but superior at the blastocyst stage. Fertility and Sterility, 2018, 110, 703-709.	1.0	27

#	Article	IF	Citations
136	Ovarian response and follow-up outcomes in women diagnosed with cancer having fertility preservation: Comparison of random start and early follicular phase stimulation - cohort study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 230, 10-14.	1.1	23
137	The Individualization of Mass Customization: Exploring the Value of Individual Thinking Style Through Consumer Neuroscience. Springer Proceedings in Business and Economics, 2018, , 439-450.	0.3	2
138	Complications of assisted reproductive technology treatment and the factors influencing reproductive outcome. The Obstetrician and Gynaecologist, 2018, 20, 177-186.	0.4	4
139	Omics Approaches in In Vitro Fertilization. , 2018, , 559-575.		0
140	Drugs Used for Controlled Ovarian Stimulation. , 2018, , 9-15.		1
141	Monitoring COS and HRT Cycles. , 2018, , 20-24.		0
142	Luteal Coasting and Individualization of Human Chorionic Gonadotropin Dose after Gonadotropin-Releasing Hormone Agonist Triggering for Final Oocyte Maturationâ€"A Retrospective Proof-of-Concept Study. Frontiers in Endocrinology, 2018, 9, 33.	3.5	11
143	Ovarian response is associated with anogenital distance in patients undergoing controlled ovarian stimulation for IVF. Human Reproduction, 2018, 33, 1696-1704.	0.9	20
144	Predicting live birth for poor ovarian responders: the PROsPeR concept. Reproductive BioMedicine Online, 2018, 37, 43-52.	2.4	13
145	Indication-oriented Ovulation Induction in Assisted Reproduction. Current Women's Health Reviews, 2018, 14, .	0.2	0
146	Clinical reassessment of human embryo ploidy status between cleavage and blastocyst stage by Next Generation Sequencing. PLoS ONE, 2018, 13, e0201652.	2.5	15
147	An overview of assisted reproductive technology procedures. The Obstetrician and Gynaecologist, 2018, 20, 167-176.	0.4	5
148	Ovulation Induction With Gonadotropins. , 2019, , 570-580.		0
149	mtDNA dynamics between cleavage-stage embryos and blastocysts. Journal of Assisted Reproduction and Genetics, 2019, 36, 1867-1875.	2.5	7
150	Cleavage stage mitochondrial DNA is correlated with preimplantation human embryo development and ploidy status. Journal of Assisted Reproduction and Genetics, 2019, 36, 1847-1854.	2.5	12
151	Common Stimulation Regimens in Assisted Reproductive Technology. , 2019, , 131-137.		0
152	Ultrasound Evaluation in Female Infertility. Obstetrics and Gynecology Clinics of North America, 2019, 46, 683-696.	1.9	8
153	What to expect from assisted reproductive technologies? Experts' forecasts for the next two decades. Technological Forecasting and Social Change, 2019, 148, 119722.	11.6	8

#	ARTICLE	IF	CITATIONS
154	Is There a Need to Alter the Timing of Anti-MÃ¼llerian Hormone Measurement During the Menstrual Cycle?. Geburtshilfe Und Frauenheilkunde, 2019, 79, 731-737.	1.8	14
155	Pharmacogenetic algorithm for individualized controlled ovarian stimulation in assisted reproductive technology cycles. Panminerva Medica, 2019, 61, 76-81.	0.8	10
156	Dual oocyte retrieval and embryo transfer in the same cycle for women with premature ovarian insufficiency. International Journal of Gynecology and Obstetrics, 2019, 145, 23-27.	2.3	3
157	Sclerostin/Receptor Related Protein 4 and Ginkgo Biloba Extract Alleviates Î²-Glycerophosphate-Induced Vascular Smooth Muscle Cell Calcification By Inhibiting Wnt/Î²-Catenin Pathway. Blood Purification, 2019, 47, 17-23.	1.8	14
158	<p>A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany</p>. International Journal of Women's Health, 2019, Volume 11, 319-331.	2.6	12
159	Antral follicle responsiveness assessed by follicular output RaTe(FORT) correlates with follicles diameter. Journal of Ovarian Research, 2019, 12, 48.	3.0	15
160	The cliniciansÂ´ dilemma with mosaicismâ€"an insight from inner cell mass biopsies. Human Reproduction, 2019, 34, 998-1010.	0.9	46
161	Anti-mÃ¼llerian Hormone for the Prediction of Ovarian Response in Progestin-Primed Ovarian Stimulation Protocol for IVF. Frontiers in Endocrinology, 2019, 10, 325.	3.5	17
162	The relationship between FSH receptor polymorphism status and IVF cycle outcome: a retrospective observational study. Reproductive BioMedicine Online, 2019, 39, 231-240.	2.4	12
163	Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification. Frontiers in Endocrinology, 2019, 10, 281.	3.5	59
164	An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patients Following the POSEIDON Criteria. Frontiers in Endocrinology, 2019, 10, 282.	3.5	31
165	A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open, 2019, 2019, hoz003.	5.4	12
166	A multicentre evaluation of the ElecsysÂ® anti-MÃ¼llerian hormone immunoassay for prediction of antral follicle count. Reproductive BioMedicine Online, 2019, 38, 845-852.	2.4	14
167	Serum antimÃ¼llerian hormone concentration increases with ovarian endometrioma size. Fertility and Sterility, 2019, 111, 944-952.e1.	1.0	20
168	Serum Anti-MÃ¼llerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study. Frontiers in Endocrinology, 2019, 10, 115.	3.5	2
169	A predictive formula for selecting individual FSH starting dose based on ovarian reserve markers in IVF/ICSI cycles. Archives of Gynecology and Obstetrics, 2019, 300, 441-446.	1.7	7
170	Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction, 2019, 34, 872-880.	0.9	64
171	The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. Reproductive Biology and Endocrinology, 2019, 17, 18.	3.3	57

#	ARTICLE	IF	CITATIONS
172	Advanced Maternal Age in IVF: Still a Challenge? The Present and the Future of Its Treatment. Frontiers in Endocrinology, 2019, 10, 94.	3.5	103
173	Anti-MÃ¼llerian Hormone and Its Predictive Utility in Assisted Reproductive Technologies Outcomes. Clinical Obstetrics and Gynecology, 2019, 62, 238-256.	1.1	12
174	Neoadjuvant Treatment With MÃ¼llerian-Inhibiting Substance Synchronizes Follicles and Enhances Superovulation Yield. Journal of the Endocrine Society, 2019, 3, 2123-2134.	0.2	12
175	Insulin-like growth factor-1 and soluble FMS-like tyrosine kinase-1 prospectively predict cancelled IVF cycles. Journal of Assisted Reproduction and Genetics, 2019, 36, 2485-2491.	2.5	10
176	Significant Serum Progesterone Variations on the Day of Final Oocyte Maturation in Stimulated IVF Cycles. Frontiers in Endocrinology, 2019, 10, 806.	3.5	5
177	Prediction of implantation after blastocyst transfer in inÂvitro fertilization: a machine-learning perspective. Fertility and Sterility, 2019, 111, 318-326.	1.0	76
178	Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reproductive BioMedicine Online, 2019, 38, 195-205.	2.4	32
179	CR-Unet: A Composite Network for Ovary and Follicle Segmentation in Ultrasound Images. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 974-983.	6.3	59
180	The importance of estradiol measurement in patients undergoing in vitro fertilization. Clinica Chimica Acta, 2020, 501, 60-65.	1.1	4
181	Isthmocele and ovarian stimulation for IVF: considerations for a reproductive medicine specialist. Human Reproduction, 2020, 35, 89-99.	0.9	23
182	Effect of deprivation on in vitro fertilisation outcome: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 458-465.	2.3	7
183	Personalized medicine for in vitro fertilization procedure using modeling and optimal control. Journal of Theoretical Biology, 2020, 487, 110105.	1.7	10
184	Elevated levels of nitrous dioxide are associated with lower AMH levels: a real-world analysis. Human Reproduction, 2020, 35, 2589-2597.	0.9	22
185	The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review. Advances in Therapy, 2020, 37, 4831-4847.	2.9	9
186	Serum anti-MÃ¼llerian hormone levels are associated with low bone mineral density in premenopausal women. Biomarkers, 2020, 25, 693-700.	1.9	5
187	<scp>Antiâ€MÃ¼llerian</scp> hormone and antral follicle count differ in their ability to predict cumulative treatment outcomes of the first complete ovarian stimulation cycle in patients from <scp>POSEIDON</scp> groups 3 and 4. Journal of Obstetrics and Gynaecology Research, 2020, 46, 1801-1808.	1.3	5
188	Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and Sterility, 2020, 114, 1151-1157.	1.0	144
189	Assessment of uterine activity during IVF by quantitative ultrasound imaging: a pilot study. Reproductive BioMedicine Online, 2020, 41, 1045-1053.	2.4	7

#	Article	IF	Citations
190	Improvement instead of stability in embryo quality between day 3-5: A possible extra predictor for blastocyst selection. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 253, 198-205.	1.1	7
191	Deep Learning based Quantification of Ovary and Follicles using 3D Transvaginal Ultrasound in Assisted Reproduction. , 2020, 2020, 2109-2112.		7
192	Affected Ovary Relative Volume: A Novel Sonographic Predictor of Ovarian Reserve in Patients with Unilateral Endometriomaâ€"A Pilot Study. Journal of Clinical Medicine, 2020, 9, 4076.	2.4	1
193	Clinical Application of AMH Measurement in Assisted Reproduction. Frontiers in Endocrinology, 2020, 11, 606744.	3.5	4
194	Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertility and Sterility, 2020, 114, 321-330.	1.0	25
195	Oocyte aneuploidyâ€"more tools to tackle an old problem. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11850-11852.	7.1	4
196	Variants in the Kisspeptin-GnRH Pathway Modulate the Hormonal Profile and Reproductive Outcomes. DNA and Cell Biology, 2020, 39, 1012-1022.	1.9	3
197	Do ovarian endometriomas affect ovarian response to ovarian stimulation for IVF/ICSI?. Reproductive BioMedicine Online, 2020, 41, 37-43.	2.4	13
198	The performance of the ElecsysÂ® anti-MÃ¼llerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa. Reproductive BioMedicine Online, 2020, 41, 29-36.	2.4	7
199	Inhibin Aâ€"A Promising Predictive Parameter for Determination of Final Oocyte Maturation in Ovarian Stimulation for IVF/ICSI. Frontiers in Endocrinology, 2020, 11, 307.	3.5	4
200	Customized modeling and optimal control of superovulation stage in in vitro fertilization (IVF) treatment. , 2020, , 383-403.		0
201	Influence of age on response to controlled ovarian stimulation in women with low levels of serum anti-MÃ¼llerian hormone. Gynecological Endocrinology, 2020, 36, 1074-1078.	1.7	4
202	Management Strategies for POSEIDON Group 2. Frontiers in Endocrinology, 2020, 11, 105.	3.5	10
203	Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations. International Journal of Molecular Sciences, 2020, 21, 2110.	4.1	34
204	Comparison of euploidy rates of blastocysts in women treated with progestins or GnRH antagonist to prevent the luteinizing hormone surge during ovarian stimulation. Human Reproduction, 2020, 35, 1325-1331.	0.9	34
205	Ageâ€specific reference ranges of serum antiâ€mÃ¼llerian hormone in healthy women and its application in diagnosis of polycystic ovary syndrome: a population study. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 720-728.	2.3	14
206	Intracytoplasmic sperm injection is not superior to conventional IVF in couples with non-male factor infertility and preimplantation genetic testing for aneuploidies (PGT-A). Human Reproduction, 2020, 35, 317-327.	0.9	41
207	Evaluation of the effect of the elective blastocyst-stage embryo transfer and freezing strategy on the abandonment of frozen embryos under the Taiwan National Assisted Reproduction Act. Journal of Assisted Reproduction and Genetics, 2020, 37, 973-982.	2.5	4

#	ARTICLE	IF	CITATIONS
208	Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty. Annals of Palliative Medicine, 2020, 9, 53-62.	1.2	4
209	Ovarian reserve markers and endocrine profile during oral contraception: Is there a link between the degree of ovarian suppression and AMH?. Gynecological Endocrinology, 2020, 36, 1090-1095.	1.7	12
210	Anti-Müllerian hormone is an independent marker for oocyte survival after vitrification. Reproductive BioMedicine Online, 2020, 41, 119-127.	2.4	3
211	A novel mathematical model of true ovarian reserve assessment based on predicted probability of poor ovarian response: a retrospective cohort study. Journal of Assisted Reproduction and Genetics, 2020, 37, 963-972.	2.5	14
212	Diagnostic value of miR-199a and miR-21 in the plasma of infertile women with dysregulated AMH levels. Human Fertility, 2022, 25, 154-165.	1.7	3
213	How fixed versus variable gonadotropin dose during controlled ovarian stimulation could influence the management of infertility patients undergoing IVF treatment: a national Delphi consensus. Gynecological Endocrinology, 2021, 37, 255-263.	1.7	5
214	Are ovarian reserve tests reliable in predicting ovarian response? Results from a prospective, cross-sectional, single-center analysis. Gynecological Endocrinology, 2021, 37, 358-366.	1.7	27
215	The risk of poor ovarian response during repeat IVF. Reproductive BioMedicine Online, 2021, 42, 742-747.	2.4	5
216	Patients with higher anti-Müllerian hormone levels from POSEIDON group 4 benefit from GnRH-agonist long protocol: A retrospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 257, 88-94.	1.1	7
217	The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in <i>in-vitro</i> fertilization cycles. Gynecological Endocrinology, 2021, 37, 372-376.	1.7	5
218	Evaluation of safety, feasibility and efficacy of intra-ovarian transplantation of autologous adipose derived mesenchymal stromal cells in idiopathic premature ovarian failure patients: non-randomized clinical trial, phase I, first in human. Journal of Ovarian Research, 2021, 14, 5.	3.0	37
219	Does blastocyst mitochondrial DNA content affect miscarriage rate in patients undergoing single euploid frozen embryo transfer?. Journal of Assisted Reproduction and Genetics, 2021, 38, 595-604.	2.5	9
220	Vitamin D in Follicular Fluid Correlates With the Euploid Status of Blastocysts in a Vitamin D Deficient Population. Frontiers in Endocrinology, 2020, 11, 609524.	3.5	4
221	Reporting on the Role of miRNAs and Affected Pathways on the Molecular Backbone of Ovarian Insufficiency: A Systematic Review and Critical Analysis Mapping of Future Research. Frontiers in Cell and Developmental Biology, 2020, 8, 590106.	3.7	2
222	Clinical Applications of Serum Anti-Müllerian Hormone Measurements in Both Males and Females: An Update. Innovation(China), 2021, 2, 100091.	9.1	18
224	Do we trust scientific evidence? A multicentre retrospective analysis of first IVF/ICSI cycles before and after the OPTIMIST trial. Human Reproduction, 2021, 36, 1367-1375.	0.9	3
225	Individualized Ovarian Stimulation for Normal and High Responders. , 2021, , 1-13.		0
226	Hormonal Ovarian Treatment. , 2021, , 71-84.		0

#	ARTICLE	IF	CITATIONS
227	Segmental duplications and monosomies are linked to in vitro developmental arrest. Journal of Assisted Reproduction and Genetics, 2021, 38, 2183-2192.	2.5	3
228	The effect of polymorphisms in <i>FSHR</i> and <i>FSHB</i> genes on ovarian response: a prospective multicenter multinational study in Europe and Asia. Human Reproduction, 2021, 36, 1711-1721.	0.9	21
229	Reproductive function of long-term treated patients with hepatic onset of Wilson's disease: a prospective study. Reproductive BioMedicine Online, 2021, 42, 835-841.	2.4	5
230	Step-Down of FSH- Dosage During Ovarian Stimulation â€" Basic Lessons to Be Learnt From a Randomized Controlled Trial. Frontiers in Endocrinology, 2021, 12, 661707.	3.5	7
231	Follitropin Delta as a State-of-the-Art Incorporated Companion for Assisted Reproductive Procedures: A Two Year Observational Study. Medicina (Lithuania), 2021, 57, 379.	2.0	4
232	Antral follicle count and anti-MÃ¼llerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients. Human Reproduction, 2021, 36, 1530-1541.	0.9	16
233	A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome. Human Reproduction, 2021, 36, 1600-1610.	0.9	2
234	Recent Advancements in Engineered Biomaterials for the Regeneration of Female Reproductive Organs. Reproductive Sciences, 2021, 28, 1612-1625.	2.5	5
235	Machine-intelligence for developing a potent signature to predict ovarian response to tailor assisted reproduction technology. Aging, 2021, 13, 17137-17154.	3.1	12
236	The clinical outcomes of fresh versus frozen embryos transfer in women â‰¥40 years with poor ovarian response. Obstetrics and Gynecology Science, 2021, 64, 284-292.	1.6	4
237	Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online, 2021, 42, 909-918.	2.4	28
238	Predictive factors of ovarian response to GnRH antagonist stimulation protocol: AMH and age are potential candidates. Middle East Fertility Society Journal, 2021, 26, .	1.5	4
239	Association between GnRH Receptor Polymorphisms and Luteinizing Hormone Levels for Low Ovarian Reserve Infertile Women. International Journal of Environmental Research and Public Health, 2021, 18, 7006.	2.6	1
240	A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction, 2021, 36, 2452-2462.	0.9	27
241	Novel nomogram-based integrated gonadotropin therapy individualization in in vitro fertilization/intracytoplasmic sperm injection: A modeling approach. Clinical and Experimental Reproductive Medicine, 2021, 48, 163-173.	1.5	11
242	Are all antral follicles the same? Size of antral follicles as a key predictor for response to controlled ovarian stimulation. Journal of Obstetrics and Gynaecology, 2022, 42, 461-466.	0.9	2
243	Characterization of micro-RNA in women with different ovarian reserve. Scientific Reports, 2021, 11, 13351.	3.3	9
244	Endocrinological and ovarian histological investigations in assigned female at birth transgender people undergoing testosterone therapy. Reproductive BioMedicine Online, 2021, 43, 289-297.	2.4	16

#	ARTICLE	IF	CITATIONS
245	Efficacy of three COS protocols and predictability of AMH and AFC in women with discordant ovarian reserve markers: a retrospective study on 19,239 patients. Journal of Ovarian Research, 2021, 14, 111.	3.0	14
246	FSH versus AMH: age-related relevance to ICSI results. Middle East Fertility Society Journal, 2021, 26, 27.	1.5	5
247	Development and Validation of a Clinical Pregnancy Failure Prediction Model for Poor Ovarian Responders During IVF/ICSI. Frontiers in Endocrinology, 2021, 12, 717288.	3.5	3
248	Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertility and Sterility, 2021, 116, 404-412.	1.0	26
249	High serum anti-Müllerian hormone concentrations have a negative impact on fertilization and embryo development rates. Reproductive BioMedicine Online, 2022, 44, 171-176.	2.4	3
250	Random antral follicle count performed on any day of the menstrual cycle has the same predictive value as AMH for good ovarian response in IVF cycles. Journal of Gynecology Obstetrics and Human Reproduction, 2022, 51, 102233.	1.3	2
251	Changing stimulation protocol on repeat conventional ovarian stimulation cycles does not lead to improved laboratory outcomes. Fertility and Sterility, 2021, 116, 757-765.	1.0	7
252	Comparison of ovarian response to follitropin delta in Japanese and White IVF/ICSI patients. Reproductive BioMedicine Online, 2022, 44, 177-184.	2.4	3
253	Correlation of TP53 (rs1625895), TP73 (rs3765730), MMP9 (rs17576), and MTHFR (rs868014) polymorphisms with low ovarian reserve. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, , .	1.1	1
254	Persistent organic pollutants and the size of ovarian reserve in reproductive-aged women. Environment International, 2021, 155, 106589.	10.0	28
255	Development of a Dynamic Diagnosis Grading System for Infertility Using Machine Learning. JAMA Network Open, 2020, 3, e2023654.	5.9	10
256	Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology. Drugs, 2020, 80, 973-994.	10.9	17
257	Ovarian biomarkers predict controlled ovarian stimulation for in vitro fertilisation treatment in Singapore. Singapore Medical Journal, 2020, 61, 463-468.	0.6	8
258	Derivation of Patient Specific Pluripotent Stem Cells Using Clinically Discarded Cumulus Cells. PLoS ONE, 2016, 11, e0165715.	2.5	2
259	Individual luteolysis pattern after GnRH-agonist trigger for final oocyte maturation. PLoS ONE, 2017, 12, e0176600.	2.5	21
260	Age-related nomograms for antral follicle count and anti-Mullerian hormone for subfertile Chinese women in Singapore. PLoS ONE, 2017, 12, e0189830.	2.5	22
261	Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk. Journal of Pediatric Endocrinology and Metabolism, 2021, 34, 25-33.	0.9	7
262	Ovarian stimulation for preimplantation genetic testing. Reproduction, 2019, 157, R127-R142.	2.6	2

#	Article	IF	Citations
263	Morphological evaluation of human oocytes in IVF practice (a review). Russian Journal of Human Reproduction, 2017, 23, 54.	0.3	1
264	Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in vitro fertilization-embryo transfer. Aging, 2020, 12, 4918-4930.	3.1	11
265	Estradiol Pretreatment in an Ultrashort GnRH Combined with a GnRH Antagonist Protocol in A Cohort of Poor Responders Undergoing IVF/ICSI: A Case-control Study. In Vivo, 2016, 30, 945-950.	1.3	7
266	A comparative study on the results of agonist and antagonist protocols based on serum AMH levels in patients undergoing intracytoplasmic sperm injection. International Journal of Reproductive BioMedicine, 2016, 14, 769-776.	0.9	6
267	Keratoconus Progression Induced by In Vitro Fertilization Treatment. Journal of Refractive Surgery, 2016, 32, 60-63.	2.3	33
268	Poor ovarian reserve. Journal of Human Reproductive Sciences, 2016, 9, 63.	0.9	67
269	Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial. Journal of Human Reproductive Sciences, 2016, 9, 164.	0.9	25
270	Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone. Journal of Research in Medical Sciences, 2016, 21, 100.	0.9	8
271	Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF?. Journal of Human Reproductive Sciences, 2017, 10, 24-30.	0.9	27
272	Controlled Ovarian Stimulation in Endometriosis Patients Can Be Individualized by Anti-Mullerian Hormone Levels. Acta Endocrinologica, 2017, 13, 195-202.	0.3	4
273	Cost-Effectiveness of the Freeze-All Policy. Jornal Brasileiro De Reproducao Assistida, 2015, 19, 125-130.	0.7	37
274	Blastocysts derived from OPN oocytes: Genetic and clinical results. Jornal Brasileiro De Reproducao Assistida, 2020, 24, 143-146.	0.7	6
275	The relationship between anti-Müllerian hormone (AMH) levels and pregnancy outcomes in patients undergoing assisted reproductive techniques (ART). PeerJ, 2020, 8, e10390.	2.0	10
276	Ethnic and Sociocultural Differences in Ovarian Reserve: Age-Specific Anti-Müllerian Hormone Values and Antral Follicle Count for Women of the Arabian Peninsula. Frontiers in Endocrinology, 2021, 12, 735116.	3.5	3
277	The Challenge of Improving IVF Results in Normogonadotrophic (Unexpected) Young Poor Ovarian Responders: The Predictive Value of a Flexible Treatment Protocol Based on the â€œBiophysical Profile of the Uterusâ€. Open Journal of Obstetrics and Gynecology, 2015, 05, 654-664.	0.2	1
278	Evaluation Prior to Controlled Ovarian Stimulation. , 2015, , 13-23.		0
279	Should you be putting all your eggs into one basket? A look into the current state and future of ovarian tissue cryopreservation.. Journal of Cancer Biology and Therapeutics, 2015, 1, .	0.0	0
280	Batch IVF Programme in ART: Practical Considerations. , 2016, , 27-50.		0

#	Article	IF	Citations
281	Relationship Between Genotype Variants Follicle-stimulating Hormone Receptor Gene Polymorphisms (FSHR) and Morphology of Oocytes Prior to ICSI Procedures. Medicinski Arhiv = Medical Archives = Archives De Médecine, 2016, 70, 364.	0.9	1
282	Mild Stimulation Protocols: Combination of Clomiphene Citrate and Recombinant FSH or HMG. , 2017, , 237-247.		0
283	Testing Ovarian Reserve. , 2017, , 43-54.		0
285	EVALUATION OF THE ROLE OF ANTIMULLERIAN HORMONE (AMH), FOLLICLE STIMULATING HORMONE (FSH) AND ANTRAL FOLLICLE COUNT (AFC) AS A PREDICTOR FOR CYCLE CANCELLATION IN WOMEN DURING ANTAGONISTIC PROTOCOL FOR ICSI. Al Azhar Medical Journal = Majallat Al-Tibb Al-Azhar, 2018, 47, 355-366.	0.1	0
286	Ovarian Stimulation Protocols. , 0, , 231-240.		0
287	Ovarian activity regulation by anti-Müllerian hormone in early stages of human female life, an overview. Anthropological Review, 2018, 81, 325-340.	0.3	1
288	Estimación ovárica para fecundación in vitro-inyección intracitoplasmática de espermatozoides en los ciclos con presunción de alta respuesta (2017). Progresos En Obstetricia Y Ginecologia, 2019, , .	0.0	0
289	Anti-Müllerian Hormone (AMH) is A Good Predictor for Ongoing Pregnancy in Women Undergoing IVF/ICSI in Antagonist Cycles. Journal of Gynecology and Womens Health, 2019, 13, .	0.1	0
290	Modelos predictivos en reproducción asistida: revisión sistemática y análisis crítico. Medicina Reproductiva Y Embriología Clínica, 2019, 6, 63-74.	0.1	0
291	Monitoring Follicular Growth. , 2020, , 121-139.		0
292	Reintroducing serum FSH measurement during ovarian stimulation for ART. Reproductive BioMedicine Online, 2022, 44, 548-556.	2.4	2
293	Personalized medicine for GnRH antagonist protocol in in vitro fertilization procedure using modeling and optimal control. Computers and Chemical Engineering, 2022, 156, 107554.	3.8	1
294	Correlation between biochemical, ultrasonographic and demographic parameters with ovarian response to IVF/ICSI treatments in Mexican women. Jornal Brasileiro De Reproducao Assistida, 2020, 25, 4-9.	0.7	2
295	AMH and Medically Assisted Reproduction. , 2020, , 31-36.		0
296	Assessment of Ovarian Reserve and Its Implications on Fertility. , 2020, , 21-30.		0
297	Endocrine Monitoring of Controlled Ovarian Stimulation for Medically Assisted Reproduction. , 2020, , 159-166.		1
299	A comparative study on the results of agonist and antagonist protocols based on serum AMH levels in patients undergoing intracytoplasmic sperm injection. International Journal of Reproductive BioMedicine, 2016, 14, 769-776.	0.9	1
300	The Effect of Different Doses of Melatonin on in Vitro Maturation of Human Follicular Fluid-Derived Oocyte-Like Cells. Jornal Brasileiro De Reproducao Assistida, 2021, , .	0.7	0

#	Article	IF	Citations
301	Metabolomic Profiling of Poor Ovarian Response Identifies Potential Predictive Biomarkers. Frontiers in Endocrinology, 2021, 12, 774667.	3.5	6
302	Age-specific distribution of serum anti-mullerian hormone and antral follicle count in Indian infertile women. Journal of Human Reproductive Sciences, 2021, 14, 372.	0.9	7
303	A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study. Reproductive Biology and Endocrinology, 2022, 20, 15.	3.3	2
304	POSEIDON 1 and 2: Probable Causes and Proposed Treatment Strategies? An Evidence-based Update. International Journal of Infertility and Fetal Medicine, 2022, 13, 23-27.	0.1	0
306	Follicular fluid and blood levels of persistent organic pollutants and reproductive outcomes among women undergoing assisted reproductive technologies. Environmental Research, 2022, 208, 112626.	7.5	25
307	Mixed-type multivariate response regression with covariance estimation. Statistics in Medicine, 2022, 41, 2768-2785.	1.6	2
308	Reliability of AMH and AFC measurements and their correlation: a large multicenter study. Journal of Assisted Reproduction and Genetics, 2022, 39, 1045-1053.	2.5	6
309	Activation of AKT/mammalian target of rapamycin signaling in the peripheral blood of women with premature ovarian insufficiency and its correlation with FMR1 expression. Reproductive Biology and Endocrinology, 2022, 20, 44.	3.3	10
310	The effect of flexible low-dose GnRH antagonist on pregnancy outcome in the fresh embryo transfer cycle of IVF-ET: a randomized controlled trial. Reproductive Biology and Endocrinology, 2022, 20, 55.	3.3	1
311	Assessment of Telomere Length and Mitochondrial DNA Copy Number in Granulosa Cells as Predictors of Aneuploidy Rate in Young Patients. Journal of Clinical Medicine, 2022, 11, 1824.	2.4	6
312	Evolution of serum progesterone levels in the very early luteal phase of stimulated IVF/ICSI cycles post hCG trigger: a proof of concept study. Journal of Assisted Reproduction and Genetics, 2022, 39, 1095-1104.	2.5	3
313	An eight centre, retrospective, clinical practice data analysis of algorithm-based treatment with follitropin delta. Reproductive BioMedicine Online, 2022, 44, 853-857.	2.4	5
314	Comparison of the number of oocytes obtained after ovarian stimulation between Chinese and Caucasian women undergoing in vitro fertilization using a standardized stimulation regime. Journal of Ovarian Research, 2021, 14, 175.	3.0	2
315	Recombinant Human Follicle-Stimulating Hormone Alfa Dose Adjustment in US Clinical Practice: An Observational, Retrospective Analysis of a Real-World Electronic Medical Records Database. Frontiers in Endocrinology, 2021, 12, 742089.	3.5	4
316	What Does Unexpected Suboptimal Response During Ovarian Stimulation Suggest, an Overlooked Group?. Frontiers in Endocrinology, 2021, 12, 795254.	3.5	4
317	Progestin-Primed Ovarian Stimulation with Clomiphene Citrate Supplementation May Be More Feasible for Young Women with Diminished Ovarian Reserve Compared with Standard Progestin-Primed Ovarian Stimulation: A Retrospective Study. Drug Design, Development and Therapy, 2021, Volume 15, 5087-5097.	4.3	2
318	Ovarian Reserve as a Guide for Ovarian Stimulation. , 2022, , 311-318.		0
319	Editorial: Ovarian Stimulation, Endocrine Responses and Impact Factors Affecting the Outcome of IVF Treatment. Frontiers in Endocrinology, 2022, 13, 857089.	3.5	0

#	ARTICLE	IF	CITATIONS
320	Ovarian Stimulation in Difficult IVF Cases. , 2022, , 109-118.		0
324	Marginal differences in preimplantation morphokinetics between conventional IVF and ICSI in patients with preimplantation genetic testing for aneuploidy (PGT-A): A sibling oocyte study. PLoS ONE, 2022, 17, e0267241.	2.5	9
325	Personalized Nutrition in the Management of Female Infertility: New Insights on Chronic Low-Grade Inflammation. Nutrients, 2022, 14, 1918.	4.1	19
326	Personalization of assisted reproductive technologies â€" myth or reality?. Russian Journal of Human Reproduction, 2022, 28, 76.	0.3	0
327	POSEIDON groups and their distinct reproductive outcomes: Effectiveness and cost-effectiveness insights from real-world data research. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 85, 159-187.	2.8	6
328	Regulatory Role and Potential Importance of GDF-8 in Ovarian Reproductive Activity. Frontiers in Endocrinology, 2022, 13, .	3.5	6
330	Serum Metabolomic Signature Predicts Ovarian Response to Controlled Stimulation. Hormone and Metabolic Research, 0, , .	1.5	0
331	Comparison of machine learning classification techniques to predict implantation success in an IVF treatment cycle. Reproductive BioMedicine Online, 2022, 45, 923-934.	2.4	5
332	Association Between the Ratio of Ovarian Stimulation Duration to Original Follicular Phase Length and In Vitro Fertilization Outcomes: A Novel Index to Optimise Clinical Trigger Time. Frontiers in Endocrinology, 0, 13, .	3.5	2
333	The case for mild stimulation for IVF: recommendations from The International Society for Mild Approaches in Assisted Reproduction. Reproductive BioMedicine Online, 2022, 45, 1133-1144.	2.4	3
334	Age-specific random day serum antimüllerian hormone reference values for women of reproductive age in the general population: a large Chinese nationwide population-based survey. American Journal of Obstetrics and Gynecology, 2022, 227, 883.e1-883.e18.	1.3	2
335	Development of a Model Predicting the Outcome of In Vitro Fertilization Cycles by a Robust Decision Tree Method. Frontiers in Endocrinology, 0, 13, .	3.5	1
336	Ovarian stimulation in assisted reproductive technology cycles for varied patient profiles: An Indian perspective. Journal of Human Reproductive Sciences, 2022, 15, 112.	0.9	2
337	A Clinician-Friendly Machine Learning System to Predict Ovarian Response and Deploy Individualized Ovarian Stimulation Strategies in IVF. SSRN Electronic Journal, 0, , .	0.4	0
339	Prospective observational comparison of arteria uterina blood flow between two frozen embryo transfer cycle regimens: natural cycle versus hormonal replacement cycle. Archives of Gynecology and Obstetrics, 0, , .	1.7	0
341	Association of follicle-to-oocyte index and clinical pregnancy in IVF treatment: A retrospective study of 4,323 fresh embryo transfer cycles. Frontiers in Endocrinology, 0, 13, .	3.5	2
342	ART outcome after euploid frozen embryo transfer is not affected by previous Cesarean section delivery in the absence of intracavitary fluid. Journal of Assisted Reproduction and Genetics, 2022, 39, 2529-2537.	2.5	1
343	Retrospective analysis of GnRH-a prolonged protocol for in vitro fertilization in 18,272 cycles in China. Journal of Ovarian Research, 2022, 15, .	3.0	0

#	Article	IF	Citations
344	Comparison of the predictive capability of antral follicle count vs. the anti-Müllerian hormone for ovarian response in infertile women. Frontiers in Endocrinology, 0, 13, .	3.5	0
345	Comparison of ART outcome in patients with poor ovarian response according to POSEIDON criteria. Scientific Reports, 2022, 12, .	3.3	3
346	The Effect of Stimulation Protocols (GnRH Agonist vs. Antagonist) on the Activity of mTOR and Hippo Pathways of Ovarian Granulosa Cells and Its Potential Correlation with the Outcomes of In Vitro Fertilization: A Hypothesis. Journal of Clinical Medicine, 2022, 11, 6131.	2.4	1
347	Impact of cystectomy versus ablation for endometrioma on ovarian reserve: a systematic review and meta-analysis. Fertility and Sterility, 2022, 118, 1172-1182.	1.0	9
348	Analysis of relative factors and prediction model for optimal ovarian response with gonadotropin-releasing hormone antagonist protocol. Frontiers in Endocrinology, 0, 13, .	3.5	1
349	A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose. Journal of Gynecology Obstetrics and Human Reproduction, 2023, 52, 102510.	1.3	3
350	Sensitive HPLC-DMS/MS/MS method coupled with dispersive magnetic solid phase extraction followed by in situ derivatization for the simultaneous determination of multiplexing androgens and 17-hydroxyprogesterone in human serum and its application to patients with polycystic ovarian syndrome. Clinica Chimica Acta, 2022, , .	1.1	3
351	Treatment algorithms for high responders: What we can learn from randomized controlled trials, real-world data and models. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2023, 86, 102301.	2.8	2
352	Quercetin alleviates cyclophosphamide-induced premature ovarian insufficiency in mice by reducing mitochondrial oxidative stress and pyroptosis in granulosa cells. Journal of Ovarian Research, 2022, 15, .	3.0	15
353	Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Frontiers in Endocrinology, 0, 13, .	3.5	8
354	Evaluation of correlation between antral follicle diameters with Follicular Output Rate (FORT) in women under controlled ovarian hyperstimulation for assisted reproductive techniques. Beni-Suef University Journal of Basic and Applied Sciences, 2022, 11, .	2.0	0
355	Effect of Superovulation Treatment on Oocyte's DNA Methylation. International Journal of Molecular Sciences, 2022, 23, 16158.	4.1	3
357	Advancements in lead therapeutic phytochemicals polycystic ovary syndrome: A review. Frontiers in Pharmacology, 0, 13, .	3.5	7
358	The Polymorphism Asn680Ser on the FSH Receptor and Abnormal Ovarian Response in Patients with Normal Values of AMH and AFC. International Journal of Molecular Sciences, 2023, 24, 1080.	4.1	2
359	The Evolution of Assisted Reproductive Technologies: A Modern Approach to Ovarian Stimulation. European Medical Journal Reproductive Health, 0, , 42-50.	1.0	0
360	Metaphase-II oocyte competence is unlinked to the gonadotrophins used for ovarian stimulation: a matched case–control study in women of advanced maternal age. Journal of Assisted Reproduction and Genetics, 2023, 40, 169-177.	2.5	2
361	Follicle Detection Model on Ovarian Ultrasound Image. , 2022, , .		0
362	The effect of large follicle puncture and aspiration on the outcomes of IVF-ET in patients with asynchronized follicles under the long GnRH-a protocol: a retrospective cohort study. BMC Pregnancy and Childbirth, 2023, 23, .	2.4	0

#	Article	IF	Citations
363	The serum follicle stimulating hormone-to-luteinizing hormone ratios can predict assisted reproductive technology outcomes in women undergoing gonadotropin releasing hormone antagonist protocol. Frontiers in Endocrinology, 0, 14, .	3.5	1
364	The gonadotropins starting dose calculator, which can be adjusted the target number of oocytes and stimulation duration days to achieve individualized controlled ovarian stimulation in Japanese patients. Reproductive Medicine and Biology, 2023, 22, .	2.4	2
365	Comparison of two different starting dose of rhFSH in GnRH antagonist protocol for patients with normal ovarian reserve. Frontiers in Endocrinology, 0, 14, .	3.5	1
366	Embryonic arrest: causes and implications. Current Opinion in Obstetrics and Gynecology, 0, Publish Ahead of Print, .	2.0	0
367	The average gonadotrophin dosage per follicle is predictive of ovarian response and cumulative live birth chances after in vitro fertilization: a retrospective cohort study. BMC Women's Health, 2023, 23, .	2.0	1
368	Serum levels of anti-Müllerian hormone influence pregnancy outcomes associated with gonadotropin-releasing hormone antagonist treatment: a retrospective cohort study. Scientific Reports, 2023, 13, .	3.3	2
369	MAY THE SYSTEMIC IMMUNE-INFLAMMATION INDEX BE AN INDICATOR OF PREMATURE OVARIAN FAILURE?. Middle Black Sea Journal of Health Science, 0, , .	0.4	0
370	Contraceptive-specific antimüllerian hormone values in reproductive-age women: a population study of 42,684 women. Fertility and Sterility, 2023, 119, 1069-1077.	1.0	4
371	Intake of soy products and soy isoflavones in relation to ovarian reserve. Fertility and Sterility, 2023, 119, 1017-1029.	1.0	3
372	Systematic review of acupuncture to improve ovarian function in women with poor ovarian response. Frontiers in Endocrinology, 0, 14, .	3.5	3
373	Effect of Frozen-Thawed Embryo Transfer on the Metabolism of Children in Early Childhood. Journal of Clinical Medicine, 2023, 12, 2322.	2.4	0
374	Recombinant follitropins in IVF programs in patients with polycystic ovary syndrome. Russian Journal of Human Reproduction, 2023, 29, 48.	0.3	0
375	Clinical and laboratory key performance indicators in IVF: A consensus between the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) and the Italian Society of Embryology, Reproduction and Research (SIERR). Journal of Assisted Reproduction and Genetics, 2023, 40, 1479-1494.	2.5	3
376	Sibling oocytes cultured in a time-lapse versus benchtop incubator: how time-lapse incubators improve blastocyst development and euploid rate. Zygote, 0, , 1-8.	1.1	0
377	Features of chromosomal abnormalities in relation to consanguinity: analysis of 10,556 blastocysts from IVF/ICSI cycles with PGT-A from consanguineous and non-consanguineous couples. Scientific Reports, 2023, 13, .	3.3	2
379	Chronic kidney disease, female infertility, and medically assisted reproduction: a best practice position statement by the Kidney and Pregnancy Group of the Italian Society of Nephrology. Journal of Nephrology, 0, , .	2.0	0
380	Antimüllerian hormone (AMH) and age as predictors of preimplantation genetic testing for aneuploidies (PGT-A) cycle outcomes and blastocyst quality on day 5 in women undergoing in vitro fertilization (IVF). Journal of Assisted Reproduction and Genetics, 2023, 40, 1467-1477.	2.5	2
383	The Ratio of Serum Progesterone (P4) to the Number of Follicles (P4/follicle) is a More Objective Parameter for Euploidy Rate as Compared to Systemic Progesterone Levels. Reproductive Sciences, 0, , .	2.5	0

#	Article	IF	Citations
384	Comparison of anti-Müllerian hormone and antral follicle count in the prediction of ovarian response: a systematic review and meta-analysis. Journal of Ovarian Research, 2023, 16, .	3.0	2
385	Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study. Advances in Therapy, 0, , .	2.9	0
386	Potential effects of assisted reproductive technology on telomere length and telomerase activity in human oocytes and early embryos. Journal of Ovarian Research, 2023, 16, .	3.0	3
388	Geç Folikÿler Fazda Rastgele Başlangıçlı Ovaryan Stimülasyon: Bir Olgu Sunumu. Jinekoloji-Obstetrik Ve Neonatoloji Tıp Dergisi, 0, , .	0.5	0
389	Predicting the total number of retrieved oocytes following double ovarian stimulation (DuoStim). Human Reproduction, 0, , .	0.9	0
390	In vitro fertilization outcomes of POSEIDON group 1b and 2b patients with suboptimal ovarian response: Retrospective analysis. Ankara Eğitim Ve Araştırma Hastanesi Tıp Dergisi, 0, , .	0.2	0
391	Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases. Journal of Ovarian Research, 2023, 16, .	3.0	0
392	Higher serum AMH level is associated with better pregnancy outcomes of IVF/ICSI assisted pregnancy in infertile patients under 35 years old. Drug Discoveries and Therapeutics, 2023, , .	1.5	0
393	How to identify patients who would benefit from delayed-matured oocytes insemination: a sibling oocyte and ploidy outcome study. Human Reproduction, 2023, 38, 1473-1483.	0.9	3
394	Transcriptomic integrity of human oocytes used in ARTs: technical and intrinsic factor effects. Human Reproduction Update, 0, , .	10.8	1
395	Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis. Frontiers in Endocrinology, 0, 14, .	3.5	0
396	The evaluation of the female infertility patient. , 2024, , 1-14.		0
397	IVF Stimulation - personalized, optimized, and simplified using an advanced decision-support tool: A randomized trial. , 2023, 1, .		0
398	Follicle-stimulating hormone receptor gene polymorphism in Albanian women. Archives of Medical Science - Civilization Diseases, 2016, 1, 87-97.	0.1	0
399	Exploring the Landscape of Social Egg Freezing: Navigating Medical Advancements, Ethical Dilemmas, and Societal Impacts. Cureus, 2023, , .	0.5	0
400	The effect of letrozole as an adjunct in GnRH-antagonist protocol on IVF/ICSI outcome in women with endometriosis: a randomized clinical trial. Middle East Fertility Society Journal, 2023, 28, .	1.5	0
401	Predicting the ovarian response: towards a determinant model and implications for practice. Journal of Assisted Reproduction and Genetics, 0, , .	2.5	0
402	Association of 'normal' early follicular FSH concentrations with unexpected poor or suboptimal response when ovarian reserve markers are reassuring: a retrospective cohort study. Reproductive BioMedicine Online, 2024, 48, 103701.	2.4	0

#	Article	IF	Citations
403	Outcome of Different Endometrial Preparation Protocols Prior to Frozen-Thawed Embryo Transfer on Pregnancy Outcomes in Women with Repeated Implantation Failure. International Journal of Women's Health, 0, Volume 15, 1835-1844.	2.6	0
404	Using feature optimization and LightGBM algorithm to predict the clinical pregnancy outcomes after in vitro fertilization. Frontiers in Endocrinology, 0, 14, .	3.5	0
405	Prospective multicenter observational real-world study to assess the use, efficacy and safety profile of follitropin delta during IVF/ICSI procedures (DELTA Study). European Journal of Obstetrics, Gynecology and Reproductive Biology, 2024, 293, 21-26.	1.1	0
406	Can AMH levels predict the need to step up FSH dose for controlled ovarian stimulation following a long GnRH agonist protocol in PCOS women?. Reproductive Biology and Endocrinology, 2023, 21, .	3.3	0
407	Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). The Cochrane Library, 2024, 2024, .	2.8	0
408	Understanding the implications of follicular output rate (FORT) and follicle to oocyte index (FOI) on human embryo morphokinetics. , 2024, 2, .		0
409	Heavy Metals and Trajectories of Anti-Müllerian Hormone During the Menopausal Transition. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	0
411	Primary sex ratio in euploid embryos of consanguine couples after IVF/ICSI. Journal of Assisted Reproduction and Genetics, 2024, 41, 957-965.	2.5	0
412	Effects of different gonadotropin preparations in GnRH antagonist protocol for patients with polycystic ovary syndrome during IVF/ICSI: a retrospective cohort study. Frontiers in Endocrinology, 0, 15, .	3.5	0
413	Association of serum uric acid with women's ovarian reserve: observational study and Mendelian randomization analyses. Fertility and Sterility, 2024, , .	1.0	0
414	Significance of serum AMH and antral follicle count discrepancy for the prediction of ovarian stimulation response in Poseidon criteria patients. Journal of Assisted Reproduction and Genetics, 2024, 41, 717-726.	2.5	0
415	Assessment of Ovarian Reserve in Women with Endometriosis. , 2024, , 81-91.		0
416	Development and validation of a prediction model for unexpected poor ovarian response during IVF/ICSI. Frontiers in Endocrinology, 0, 15, .	3.5	0
417	Autophagy activity is increased in the cumulus cells of women with poor ovarian response. Taiwanese Journal of Obstetrics and Gynecology, 2024, 63, 205-213.	1.3	0